IASON Gmbh   Report issue

For profit Phase 2
Founded: Graz Seiersberg Austria (1994)
Status: No NME R&D (1994)

Organization Overview

First Clinical Trial
2012
NCT01898065
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Alternative names

IASON Gmbh, Feldkirchner strasse 4, 8054 Graz-Seiesberg AUSTRIA

Active Ingredients

Drugs in Phase 2 Trials (1)

fluoromisonidazole (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Hypoxia (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1